Alignment Healthcare, Inc. (ALHC)
Last Price$15.5(1.1%)
Market Cap$3,104.9M
ALHC Rating
ALHC Quality rating performance
ALHC Intrinsic Value
Key Highlights:
As of Mar 03, 2025 ALHC Relative Value is $8.6, which is overvalued by 44.6%, compared to current share price of $15.5.
As of Mar 03, 2025 ALHC DCF Value is N/A, which is undervalued by N/A, compared to current share price of $15.5.
ALHC Share Price History
1W 13.9%
1M 1.0%
6M 58.2%
YTD 82.8%
1Y 187.4%
3Y 87.0%
5Y (10.3%)
10Y (10.3%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
ALHC Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$3,104.9M
$2,679.9M
$2,703.6M
($6,648.0K)
Shares Outstanding
200M
Employees
N/A
Growth (CAGR)
N/A
N/A
46.8%
(13.32%)
Profitability
33.7%
(3.8%)
(4.7%)
1.3%
(0.2%)
5.2%
Intrinsic Value
$8.2 (47.0% overvalued)
N/A
$8.2
(100.0%)
(49.0%)
Valuation (LTM)
Return on Capital
Financial Health
($425.0M)
63.9x
(4.3x)
Dividends
Earnings
Apr 30, 2025
BEAT by 2.4%
MISS by 0.0%
(22.2%)
5 Beat & 5 Miss
ALHC Stock Financials
ALHC Income Statement Metrics
Annual
Quarterly
LTM
ALHC Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
($59.2M) +30.3% YoY
Capital Expenditure (CAPEX)
($36.0M) +51.4% YoY
Free Cash Flow (FCF)
($95.2M) +37.5% YoY
ALHC Income Statement Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
ALHC Balance Sheet Overview
Annual
Quarterly
LTM
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$591.9M
Current assets ($483.5M, 81.7% of total)
$318.8M (53.9%)
$119.7M (20.2%)
Other current assets
$45.0M (7.6%)
Non-current assets ($108.3M, 18.3% of total)
$0.0 (0.0%)
$61.9M (10.5%)
$5,252.0K (0.9%)
Other non-current assets
$41.2M (7.0%)
Financial position
($148.0M)
Cash & Short-term
Investments
Total Debt
ALHC Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
ALHC Earnings Surprises
Crunching data... Almost there!
ALHC Dividends
ALHC Dividend Yield
Crunching data... Almost there!
ALHC Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with ALHC
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$3,104.9M | 5.4 | $8.2 47.0% overvalued | 187.4% | $2,703.6M | ($6,648.0K) | 48.3% | (0.2%) | 33.7% | (41.1%) | 7.8% | |
$436.0B | 5.9 | $1,047.3 124.2% undervalued | (1.6%) | $398.3B | $20.7B | 8.4% | 5.2% | 21.9% | 28.1% | 1.5% | |
$90.7B | 6.7 | $1,001.8 153.3% undervalued | (20.5%) | $176.8B | $4,552.0M | 3.2% | 2.6% | 43.4% | 161.3% | 4.9% | |
$87.2B | 5.8 | $942.9 202.7% undervalued | (6.0%) | $245.3B | $8,957.0M | 25.7% | 3.7% | 48.9% | 4.9% | 77.5% | |
$82.3B | 5.1 | $208.2 220.8% undervalued | (9.3%) | $372.8B | $6,326.0M | 4.2% | 1.7% | 13.8% | 3.7% | 109.5% | |
$31.5B | 6.1 | $797.8 205.0% undervalued | (23.7%) | $117.8B | $2,391.0M | 10.7% | 2.0% | 91.9% | 58.6% | 71.3% | |
$29.1B | 5.4 | $1,406.9 2,301.3% undervalued | (25.2%) | $163.1B | ($490.0M) | 5.9% | (0.3%) | 13.1% | 12.0% | 69.9% | |
$17.3B | 6.3 | $414.9 37.0% undervalued | (21.7%) | $40.6B | $544.0M | 19.2% | 1.3% | 34.7% | 33.0% | 69.4% | |
$3,703.3M | 6.1 | $23.7 57.0% undervalued | (1.7%) | $9,177.6M | $950.3M | 56.6% | 10.4% | 100.0% | (15.2%) | 29.5% | |
$1,871.6M | 5.2 | $2.0 45.3% overvalued | 330.8% | $1,370.6M | $128.3M | (32.4%) | 9.4% | 53.9% | 1.2% | 0.0% | |
$65.5M | 5.0 | $46.2 463.3% undervalued | (85.9%) | $1,616.6M | ($2,834.8M) | (71.1%) | (175.4%) | 7.8% | (63.3%) | (145.5%) |
FAQ
What is Alignment Healthcare, Inc. (ALHC) stock rating?
As of today, Alignment Healthcare, Inc. has a stock rating of 5 (out of 10), which is considered Good.
is Alignment Healthcare, Inc. (ALHC) a good stock to buy?
As of today, Alignment Healthcare, Inc. has a Good stock rating, which is 47.0% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.